PP
AKRO

PDT Partners’s Akero Therapeutics AKRO Stock Holding History

PDT Partners’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,847
Closed -$601K – 683
2025
Q1 		$601K Sell
14,847
-122,183
-89% -$5.18M 0.04% 491
2024
Q4 		$3.81M Sell
137,030
-2,266
-2% -$68.6K 0.34% 85
2024
Q3 		$4M Hold
139,296
– – 0.35% 58
2024
Q2 		$3.27M Buy
139,296
+14,848
+12% +$318K 0.31% 93
2024
Q1 		$3.14M Buy
+124,448
New +$2.99M 0.3% 104
2022
Q4 		– Sell
-24,593
Closed -$837K – 617
2022
Q3 		$837K Sell
24,593
-14,279
-37% -$218K 0.13% 269
2022
Q2 		$367K Buy
+38,872
New +$405K 0.03% 693

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PDT Partners's AKRO Position: Q2 2025 in Review

PDT Partners sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 14,847 shares — an estimated $601K sold.

PDT Partners first reported a position in AKRO in Q2 2022 and held it in 7 quarters. The position peaked at $4M in Q3 2024. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

  • PDT Partners reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • PDT Partners sold 14,847 Akero Therapeutics shares in Q2 2025, an estimated $601K.
  • PDT Partners first reported a position in Akero Therapeutics in Q2 2022 and held it in 7 quarters.
  • PDT Partners's Akero Therapeutics position peaked at $4M in Q3 2024.
  • 257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on PDT Partners's 13F filing for Q2 2025, filed 14 Aug 2025.